A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity

Authors: Ute Klinkhardt, Mirjam Schunk, John Ervin, Christoph Schindler, Danny Sugimoto, Bruce Rankin, Ralf Amann, Martina Monti, Anna Kutschenko, Carsten Schumacher, Kristina Huber, Andreas Zeder, Nelli Heikkila, Arnaud M. Didierlaurent, Sylvia E. Schwarz, Madiha Derouazi

Source: Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)

Subject Terms: SARS-CoV-2 variants, COVID-19, booster vaccine, ORF virus-vector, first-in-human trial, immunogenicity, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://doaj.org/toc/2164-5515; https://doaj.org/toc/2164-554X

Access URL: https://doaj.org/article/ac42958aa7f6453581c61e1316c600ce

Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors

Authors: Jiani Wang, Lin Gui, Yuxin Mu, Jiayu Wang, Yihebali Chi, Zhenteng Liu, Qing Li, Binghe Xu

Source: BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)

Subject Terms: LXI-15029, mTORC1/2 dual inhibitor, Metastatic solid tumors, First-in-human trial, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/0116ecedf75541d9827069d3e5bddbc2

First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody

Authors: Tingting Ma, Bei Cao, Lei Huang, Yuanxun Yang, Yan Geng, Pinhao Xie, Yu Zhao, Hui Lin, Kun Wang, Chunhe Wang, Runbin Sun, Juan Li

Source: Frontiers in Pharmacology, Vol 13 (2022)

Subject Terms: DS002, anti-nerve growth factor antibody, first-in-human trial, pharmacodynamics, novel analgesic, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2022.1075309/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/a5cc87f1d96144faa796463962b53df9

A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

Authors: Pin Zhang, Binghe Xu, Lin Gui, Wenna Wang, Meng Xiu, Xiao Zhang, Guilan Sun, Xiaoyu Zhu, Jianjun Zou

Source: Biomarker Research, Vol 9, Iss 1, Pp 1-9 (2021)

Subject Terms: Cyclin-dependent kinase 4/6 inhibitor, Advanced breast cancer, First-in-human trial, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://doaj.org/toc/2050-7771

Access URL: https://doaj.org/article/d90b26c5c0984e26bded0075c4324f98

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Authors: Joel Z. Nordin, author¹, Yoshitaka Mizobe, author¹, Harumasa Nakamura, author², Hirofumi Komaki, author³, Shin'ichi Takeda, author¹, Yoshitsugu Aoki, author¹

Source: Journal of Visualized Experiments. (159)

Availability: http://www.jove.com/video/60672

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects

Authors: Rui Chen, Xiaoduo Guan, Pei Hu, Yanli Dong, Yi Zhu, Tengfei Zhang, Jianjun Zou, Shuyang Zhang

Source: Frontiers in Pharmacology, Vol 13 (2022)

Subject Terms: anticoagulant, factor XI inhibitor, first-in-human trial, SHR2285, pharmacokinetics, pharmacodynamics, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2022.821363/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/7478991a374e49fab0b5c950db5783f7

A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients

Authors: Anne-Laure Giraudet, Philippe Alexandre Cassier, Chicaco Iwao-Fukukawa, Gwenaelle Garin, Jean-Noël Badel, David Kryza, Sylvie Chabaud, Laurence Gilles-Afchain, Gilles Clapisson, Claude Desuzinges, David Sarrut, Adrien Halty, Antoine Italiano, Masaharu Mori, Takuya Tsunoda, Toyomasa Katagiri, Yusuke Nakamura, Laurent Alberti, Claire Cropet, Simon Baconnier, Sandrine Berge-Montamat, David Pérol, Jean-Yves Blay

Source: BMC Cancer, Vol 18, Iss 1, Pp 1-13 (2018)

Subject Terms: Synovial sarcoma, Radioimmunotherapy, Theranostic, First-in-human trial, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s12885-018-4544-x; https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/f7e4c42b865f4a648c225b6c01e4f105

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.